Pacira BioSciences (PCRX) Stock: Buy, Sell, or Hold?
PCRX - Pacira BioSciences, Inc. Common Stock
$25.36
0.20 (0.79%)
â˛
5d:
-4.66%
30d:
+7.0%
90d:
+8.56%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When PCRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: PCRX is fairly priced but lacks strong directional signals. At 2.8% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: PCRX is fairly priced but lacks strong directional signals. At 2.8% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$40.82
Based on 11.9% avg growth
INTRINSIC VALUE TODAY
$25.34
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PCRX is currently trading at $25.36, which is considered fair relative to its 30-day fair value range of $24.00 to $26.28. The stock's valuation (Forward PE: 7.3) is in line with its historical norms (6.8). At these levels, the market is pricing in 2.8% annual earnings growth.
Technical Outlook: Technically, PCRX is in a uptrend. The price is currently testing key support at $25.10. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PCRX scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $30.00 (+18.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PCRX is in a uptrend. The price is currently testing key support at $25.10. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PCRX scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $30.00 (+18.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$24.00 -
$26.28
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
51.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (39/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($30.00)
- BULLISH: Expecting earnings turnaround to 2.8% growth with 6.2% revenue growth
- WARNING: Composite score 48/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$24.00 -
$26.28
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$25.10
Resistance Level
$26.91
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.35
Wall Street Target
$30.00
(+18.3%)
Revenue Growth (YoY)
6.2%
Earnings Growth (YoY)
-30.0%
Profit Margin
2.0%
Valuation Premium vs History
+2.8% premium
PE vs Historical
7.4 vs 6.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.8%
(market-implied from PE analysis)
1-Year Target
$26.07
(+3%)
2-Year Target
$26.80
(+6%)
3-Year Target
$27.55
(+9%)
3-Yr Target (if PE normalizes)
(PE: 7â7)
PE COMPRESSION
$25.49
(+1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 19.7%)
$119.20
(+370%)
Base:
(SPY PE: 7.4, Growth: 19.7%)
$43.44
(+71%)
Bear:
(PE: 6.2, Growth: 19.7%)
$36.92
(+46%)
đ
Valuation based on Current Earnings
Forward PE: 6.57 | Forward EPS (Implied): $3.86
Bull Case
$30.62
(+21%)
Analyst growth 15.0%, PE expands to 6.9
Base Case
$25.36
(0%)
Market implied 0.0%, PE stable at 6.6
Bear Case
$19.40
(-24%)
Severe decline -15.0%, PE contracts to 5.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 12, 2026 12:04 PM ET
Data refreshes hourly during market hours. Next update: 1:04 PM
Data refreshes hourly during market hours. Next update: 1:04 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PCRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Shawn Cross
SELL
12941 shares
2026-04-23
Shawn Cross
SELL
1500 shares
2026-04-22
Shawn Cross
SELL
2845 shares
2026-04-21
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$212 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary ShâĻ |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
